WNK1 and heart failure: In vivo testing of senolytic, WNK1 inhibitor, and anti-syncytia drug implicated senescence syncytia as a central driver in promoting heart failure progression, highlighting the clinical potential of WNK1 inhibitors as a novel interventional therapeutic strategy.